nodes	percent_of_prediction	percent_of_DWPC	metapath
Frovatriptan—migraine—Prednisone—hematologic cancer	0.474	1	CpDpCtD
Frovatriptan—CYP1A2—Anagrelide—hematologic cancer	0.0597	0.217	CbGbCtD
Frovatriptan—CYP1A2—Carmustine—hematologic cancer	0.0314	0.114	CbGbCtD
Frovatriptan—CYP1A2—Methoxsalen—hematologic cancer	0.0267	0.097	CbGbCtD
Frovatriptan—CYP1A2—Bortezomib—hematologic cancer	0.0254	0.0922	CbGbCtD
Frovatriptan—CYP1A2—Daunorubicin—hematologic cancer	0.0243	0.0882	CbGbCtD
Frovatriptan—CYP1A2—Alitretinoin—hematologic cancer	0.0238	0.0864	CbGbCtD
Frovatriptan—CYP1A2—Thalidomide—hematologic cancer	0.0221	0.0803	CbGbCtD
Frovatriptan—CYP1A2—Dacarbazine—hematologic cancer	0.019	0.0691	CbGbCtD
Frovatriptan—CYP1A2—Imatinib—hematologic cancer	0.0186	0.0676	CbGbCtD
Frovatriptan—CYP1A2—Dasatinib—hematologic cancer	0.0149	0.0543	CbGbCtD
Frovatriptan—CYP1A2—Etoposide—hematologic cancer	0.0093	0.0338	CbGbCtD
Frovatriptan—Headache—Irinotecan—hematologic cancer	3.04e-05	0.000133	CcSEcCtD
Frovatriptan—Nausea—Ifosfamide—hematologic cancer	3.04e-05	0.000133	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	3.03e-05	0.000132	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Betamethasone—hematologic cancer	3.03e-05	0.000132	CcSEcCtD
Frovatriptan—Myalgia—Prednisone—hematologic cancer	3.02e-05	0.000132	CcSEcCtD
Frovatriptan—Arthralgia—Prednisone—hematologic cancer	3.02e-05	0.000132	CcSEcCtD
Frovatriptan—Feeling abnormal—Triamcinolone—hematologic cancer	3.02e-05	0.000132	CcSEcCtD
Frovatriptan—Diarrhoea—Cisplatin—hematologic cancer	3.02e-05	0.000132	CcSEcCtD
Frovatriptan—Anxiety—Prednisone—hematologic cancer	3.01e-05	0.000131	CcSEcCtD
Frovatriptan—Vomiting—Gemcitabine—hematologic cancer	3.01e-05	0.000131	CcSEcCtD
Frovatriptan—Insomnia—Betamethasone—hematologic cancer	3.01e-05	0.000131	CcSEcCtD
Frovatriptan—Insomnia—Dexamethasone—hematologic cancer	3.01e-05	0.000131	CcSEcCtD
Frovatriptan—Bradycardia—Doxorubicin—hematologic cancer	3e-05	0.000131	CcSEcCtD
Frovatriptan—Paraesthesia—Dexamethasone—hematologic cancer	2.99e-05	0.00013	CcSEcCtD
Frovatriptan—Paraesthesia—Betamethasone—hematologic cancer	2.99e-05	0.00013	CcSEcCtD
Frovatriptan—Discomfort—Prednisone—hematologic cancer	2.99e-05	0.00013	CcSEcCtD
Frovatriptan—Mental disorder—Methotrexate—hematologic cancer	2.99e-05	0.00013	CcSEcCtD
Frovatriptan—Hypersensitivity—Etoposide—hematologic cancer	2.98e-05	0.00013	CcSEcCtD
Frovatriptan—Tinnitus—Epirubicin—hematologic cancer	2.97e-05	0.00013	CcSEcCtD
Frovatriptan—Malnutrition—Methotrexate—hematologic cancer	2.97e-05	0.000129	CcSEcCtD
Frovatriptan—Haemoglobin—Doxorubicin—hematologic cancer	2.97e-05	0.000129	CcSEcCtD
Frovatriptan—Headache—Gemcitabine—hematologic cancer	2.97e-05	0.000129	CcSEcCtD
Frovatriptan—Nausea—Vincristine—hematologic cancer	2.96e-05	0.000129	CcSEcCtD
Frovatriptan—Flushing—Epirubicin—hematologic cancer	2.96e-05	0.000129	CcSEcCtD
Frovatriptan—Rhinitis—Doxorubicin—hematologic cancer	2.96e-05	0.000129	CcSEcCtD
Frovatriptan—Haemorrhage—Doxorubicin—hematologic cancer	2.95e-05	0.000129	CcSEcCtD
Frovatriptan—Hypersensitivity—Prednisolone—hematologic cancer	2.94e-05	0.000128	CcSEcCtD
Frovatriptan—Hypoaesthesia—Doxorubicin—hematologic cancer	2.94e-05	0.000128	CcSEcCtD
Frovatriptan—Pharyngitis—Doxorubicin—hematologic cancer	2.93e-05	0.000128	CcSEcCtD
Frovatriptan—Dyspepsia—Betamethasone—hematologic cancer	2.93e-05	0.000128	CcSEcCtD
Frovatriptan—Dyspepsia—Dexamethasone—hematologic cancer	2.93e-05	0.000128	CcSEcCtD
Frovatriptan—Urinary tract disorder—Doxorubicin—hematologic cancer	2.91e-05	0.000127	CcSEcCtD
Frovatriptan—Dysgeusia—Methotrexate—hematologic cancer	2.91e-05	0.000127	CcSEcCtD
Frovatriptan—Asthenia—Etoposide—hematologic cancer	2.9e-05	0.000126	CcSEcCtD
Frovatriptan—Body temperature increased—Triamcinolone—hematologic cancer	2.9e-05	0.000126	CcSEcCtD
Frovatriptan—Anaphylactic shock—Prednisone—hematologic cancer	2.9e-05	0.000126	CcSEcCtD
Frovatriptan—Urethral disorder—Doxorubicin—hematologic cancer	2.89e-05	0.000126	CcSEcCtD
Frovatriptan—Decreased appetite—Betamethasone—hematologic cancer	2.89e-05	0.000126	CcSEcCtD
Frovatriptan—Decreased appetite—Dexamethasone—hematologic cancer	2.89e-05	0.000126	CcSEcCtD
Frovatriptan—Nausea—Mitoxantrone—hematologic cancer	2.89e-05	0.000126	CcSEcCtD
Frovatriptan—Nausea—Irinotecan—hematologic cancer	2.89e-05	0.000126	CcSEcCtD
Frovatriptan—Back pain—Methotrexate—hematologic cancer	2.87e-05	0.000125	CcSEcCtD
Frovatriptan—Fatigue—Dexamethasone—hematologic cancer	2.87e-05	0.000125	CcSEcCtD
Frovatriptan—Fatigue—Betamethasone—hematologic cancer	2.87e-05	0.000125	CcSEcCtD
Frovatriptan—Chills—Epirubicin—hematologic cancer	2.86e-05	0.000125	CcSEcCtD
Frovatriptan—Pruritus—Etoposide—hematologic cancer	2.86e-05	0.000125	CcSEcCtD
Frovatriptan—Shock—Prednisone—hematologic cancer	2.85e-05	0.000124	CcSEcCtD
Frovatriptan—Arrhythmia—Epirubicin—hematologic cancer	2.85e-05	0.000124	CcSEcCtD
Frovatriptan—Pain—Betamethasone—hematologic cancer	2.85e-05	0.000124	CcSEcCtD
Frovatriptan—Pain—Dexamethasone—hematologic cancer	2.85e-05	0.000124	CcSEcCtD
Frovatriptan—Visual impairment—Doxorubicin—hematologic cancer	2.84e-05	0.000124	CcSEcCtD
Frovatriptan—Tachycardia—Prednisone—hematologic cancer	2.83e-05	0.000123	CcSEcCtD
Frovatriptan—Nausea—Gemcitabine—hematologic cancer	2.81e-05	0.000123	CcSEcCtD
Frovatriptan—Vomiting—Cisplatin—hematologic cancer	2.81e-05	0.000122	CcSEcCtD
Frovatriptan—Hyperhidrosis—Prednisone—hematologic cancer	2.8e-05	0.000122	CcSEcCtD
Frovatriptan—Mental disorder—Epirubicin—hematologic cancer	2.79e-05	0.000122	CcSEcCtD
Frovatriptan—Malnutrition—Epirubicin—hematologic cancer	2.78e-05	0.000121	CcSEcCtD
Frovatriptan—Diarrhoea—Etoposide—hematologic cancer	2.77e-05	0.000121	CcSEcCtD
Frovatriptan—Anorexia—Prednisone—hematologic cancer	2.76e-05	0.00012	CcSEcCtD
Frovatriptan—Ill-defined disorder—Methotrexate—hematologic cancer	2.75e-05	0.00012	CcSEcCtD
Frovatriptan—Tinnitus—Doxorubicin—hematologic cancer	2.75e-05	0.00012	CcSEcCtD
Frovatriptan—Feeling abnormal—Betamethasone—hematologic cancer	2.74e-05	0.00012	CcSEcCtD
Frovatriptan—Feeling abnormal—Dexamethasone—hematologic cancer	2.74e-05	0.00012	CcSEcCtD
Frovatriptan—Flushing—Doxorubicin—hematologic cancer	2.74e-05	0.000119	CcSEcCtD
Frovatriptan—Flatulence—Epirubicin—hematologic cancer	2.74e-05	0.000119	CcSEcCtD
Frovatriptan—Tension—Epirubicin—hematologic cancer	2.72e-05	0.000119	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Betamethasone—hematologic cancer	2.72e-05	0.000119	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.72e-05	0.000119	CcSEcCtD
Frovatriptan—Dysgeusia—Epirubicin—hematologic cancer	2.72e-05	0.000119	CcSEcCtD
Frovatriptan—Hypersensitivity—Triamcinolone—hematologic cancer	2.7e-05	0.000118	CcSEcCtD
Frovatriptan—Nervousness—Epirubicin—hematologic cancer	2.7e-05	0.000118	CcSEcCtD
Frovatriptan—Back pain—Epirubicin—hematologic cancer	2.69e-05	0.000117	CcSEcCtD
Frovatriptan—Malaise—Methotrexate—hematologic cancer	2.68e-05	0.000117	CcSEcCtD
Frovatriptan—Dizziness—Etoposide—hematologic cancer	2.67e-05	0.000117	CcSEcCtD
Frovatriptan—Muscle spasms—Epirubicin—hematologic cancer	2.67e-05	0.000116	CcSEcCtD
Frovatriptan—Vertigo—Methotrexate—hematologic cancer	2.67e-05	0.000116	CcSEcCtD
Frovatriptan—Chills—Doxorubicin—hematologic cancer	2.65e-05	0.000115	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Prednisone—hematologic cancer	2.64e-05	0.000115	CcSEcCtD
Frovatriptan—Dizziness—Prednisolone—hematologic cancer	2.64e-05	0.000115	CcSEcCtD
Frovatriptan—Arrhythmia—Doxorubicin—hematologic cancer	2.64e-05	0.000115	CcSEcCtD
Frovatriptan—Asthenia—Triamcinolone—hematologic cancer	2.63e-05	0.000115	CcSEcCtD
Frovatriptan—Abdominal pain—Betamethasone—hematologic cancer	2.63e-05	0.000115	CcSEcCtD
Frovatriptan—Body temperature increased—Betamethasone—hematologic cancer	2.63e-05	0.000115	CcSEcCtD
Frovatriptan—Abdominal pain—Dexamethasone—hematologic cancer	2.63e-05	0.000115	CcSEcCtD
Frovatriptan—Body temperature increased—Dexamethasone—hematologic cancer	2.63e-05	0.000115	CcSEcCtD
Frovatriptan—Nausea—Cisplatin—hematologic cancer	2.62e-05	0.000114	CcSEcCtD
Frovatriptan—Insomnia—Prednisone—hematologic cancer	2.62e-05	0.000114	CcSEcCtD
Frovatriptan—Paraesthesia—Prednisone—hematologic cancer	2.6e-05	0.000113	CcSEcCtD
Frovatriptan—Pruritus—Triamcinolone—hematologic cancer	2.59e-05	0.000113	CcSEcCtD
Frovatriptan—Mental disorder—Doxorubicin—hematologic cancer	2.59e-05	0.000113	CcSEcCtD
Frovatriptan—Ill-defined disorder—Epirubicin—hematologic cancer	2.58e-05	0.000112	CcSEcCtD
Frovatriptan—Convulsion—Methotrexate—hematologic cancer	2.57e-05	0.000112	CcSEcCtD
Frovatriptan—Vomiting—Etoposide—hematologic cancer	2.57e-05	0.000112	CcSEcCtD
Frovatriptan—Malnutrition—Doxorubicin—hematologic cancer	2.57e-05	0.000112	CcSEcCtD
Frovatriptan—Agitation—Epirubicin—hematologic cancer	2.55e-05	0.000111	CcSEcCtD
Frovatriptan—Dyspepsia—Prednisone—hematologic cancer	2.55e-05	0.000111	CcSEcCtD
Frovatriptan—Headache—Etoposide—hematologic cancer	2.53e-05	0.00011	CcSEcCtD
Frovatriptan—Flatulence—Doxorubicin—hematologic cancer	2.53e-05	0.00011	CcSEcCtD
Frovatriptan—Myalgia—Methotrexate—hematologic cancer	2.53e-05	0.00011	CcSEcCtD
Frovatriptan—Chest pain—Methotrexate—hematologic cancer	2.53e-05	0.00011	CcSEcCtD
Frovatriptan—Arthralgia—Methotrexate—hematologic cancer	2.53e-05	0.00011	CcSEcCtD
Frovatriptan—Tension—Doxorubicin—hematologic cancer	2.52e-05	0.00011	CcSEcCtD
Frovatriptan—Decreased appetite—Prednisone—hematologic cancer	2.52e-05	0.00011	CcSEcCtD
Frovatriptan—Dysgeusia—Doxorubicin—hematologic cancer	2.52e-05	0.00011	CcSEcCtD
Frovatriptan—Malaise—Epirubicin—hematologic cancer	2.5e-05	0.000109	CcSEcCtD
Frovatriptan—Fatigue—Prednisone—hematologic cancer	2.5e-05	0.000109	CcSEcCtD
Frovatriptan—Headache—Prednisolone—hematologic cancer	2.5e-05	0.000109	CcSEcCtD
Frovatriptan—Discomfort—Methotrexate—hematologic cancer	2.5e-05	0.000109	CcSEcCtD
Frovatriptan—Nervousness—Doxorubicin—hematologic cancer	2.5e-05	0.000109	CcSEcCtD
Frovatriptan—Vertigo—Epirubicin—hematologic cancer	2.49e-05	0.000109	CcSEcCtD
Frovatriptan—Syncope—Epirubicin—hematologic cancer	2.49e-05	0.000109	CcSEcCtD
Frovatriptan—Back pain—Doxorubicin—hematologic cancer	2.49e-05	0.000108	CcSEcCtD
Frovatriptan—Constipation—Prednisone—hematologic cancer	2.48e-05	0.000108	CcSEcCtD
Frovatriptan—Muscle spasms—Doxorubicin—hematologic cancer	2.47e-05	0.000108	CcSEcCtD
Frovatriptan—Palpitations—Epirubicin—hematologic cancer	2.45e-05	0.000107	CcSEcCtD
Frovatriptan—Confusional state—Methotrexate—hematologic cancer	2.44e-05	0.000106	CcSEcCtD
Frovatriptan—Loss of consciousness—Epirubicin—hematologic cancer	2.44e-05	0.000106	CcSEcCtD
Frovatriptan—Dizziness—Triamcinolone—hematologic cancer	2.42e-05	0.000106	CcSEcCtD
Frovatriptan—Anaphylactic shock—Methotrexate—hematologic cancer	2.42e-05	0.000106	CcSEcCtD
Frovatriptan—Convulsion—Epirubicin—hematologic cancer	2.41e-05	0.000105	CcSEcCtD
Frovatriptan—Nausea—Etoposide—hematologic cancer	2.4e-05	0.000105	CcSEcCtD
Frovatriptan—Feeling abnormal—Prednisone—hematologic cancer	2.39e-05	0.000104	CcSEcCtD
Frovatriptan—Asthenia—Betamethasone—hematologic cancer	2.39e-05	0.000104	CcSEcCtD
Frovatriptan—Asthenia—Dexamethasone—hematologic cancer	2.39e-05	0.000104	CcSEcCtD
Frovatriptan—Ill-defined disorder—Doxorubicin—hematologic cancer	2.38e-05	0.000104	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Prednisone—hematologic cancer	2.37e-05	0.000103	CcSEcCtD
Frovatriptan—Nausea—Prednisolone—hematologic cancer	2.37e-05	0.000103	CcSEcCtD
Frovatriptan—Arthralgia—Epirubicin—hematologic cancer	2.36e-05	0.000103	CcSEcCtD
Frovatriptan—Chest pain—Epirubicin—hematologic cancer	2.36e-05	0.000103	CcSEcCtD
Frovatriptan—Myalgia—Epirubicin—hematologic cancer	2.36e-05	0.000103	CcSEcCtD
Frovatriptan—Agitation—Doxorubicin—hematologic cancer	2.36e-05	0.000103	CcSEcCtD
Frovatriptan—Anxiety—Epirubicin—hematologic cancer	2.36e-05	0.000103	CcSEcCtD
Frovatriptan—Pruritus—Dexamethasone—hematologic cancer	2.35e-05	0.000103	CcSEcCtD
Frovatriptan—Pruritus—Betamethasone—hematologic cancer	2.35e-05	0.000103	CcSEcCtD
Frovatriptan—Hyperhidrosis—Methotrexate—hematologic cancer	2.34e-05	0.000102	CcSEcCtD
Frovatriptan—Discomfort—Epirubicin—hematologic cancer	2.34e-05	0.000102	CcSEcCtD
Frovatriptan—Vomiting—Triamcinolone—hematologic cancer	2.33e-05	0.000102	CcSEcCtD
Frovatriptan—Malaise—Doxorubicin—hematologic cancer	2.32e-05	0.000101	CcSEcCtD
Frovatriptan—Dry mouth—Epirubicin—hematologic cancer	2.31e-05	0.000101	CcSEcCtD
Frovatriptan—Vertigo—Doxorubicin—hematologic cancer	2.31e-05	0.000101	CcSEcCtD
Frovatriptan—Anorexia—Methotrexate—hematologic cancer	2.31e-05	0.000101	CcSEcCtD
Frovatriptan—Syncope—Doxorubicin—hematologic cancer	2.3e-05	0.0001	CcSEcCtD
Frovatriptan—Headache—Triamcinolone—hematologic cancer	2.3e-05	0.0001	CcSEcCtD
Frovatriptan—Abdominal pain—Prednisone—hematologic cancer	2.29e-05	9.99e-05	CcSEcCtD
Frovatriptan—Body temperature increased—Prednisone—hematologic cancer	2.29e-05	9.99e-05	CcSEcCtD
Frovatriptan—Confusional state—Epirubicin—hematologic cancer	2.29e-05	9.96e-05	CcSEcCtD
Frovatriptan—Diarrhoea—Betamethasone—hematologic cancer	2.28e-05	9.93e-05	CcSEcCtD
Frovatriptan—Diarrhoea—Dexamethasone—hematologic cancer	2.28e-05	9.93e-05	CcSEcCtD
Frovatriptan—Palpitations—Doxorubicin—hematologic cancer	2.27e-05	9.9e-05	CcSEcCtD
Frovatriptan—Anaphylactic shock—Epirubicin—hematologic cancer	2.27e-05	9.88e-05	CcSEcCtD
Frovatriptan—Loss of consciousness—Doxorubicin—hematologic cancer	2.26e-05	9.85e-05	CcSEcCtD
Frovatriptan—Shock—Epirubicin—hematologic cancer	2.23e-05	9.72e-05	CcSEcCtD
Frovatriptan—Convulsion—Doxorubicin—hematologic cancer	2.23e-05	9.71e-05	CcSEcCtD
Frovatriptan—Tachycardia—Epirubicin—hematologic cancer	2.21e-05	9.64e-05	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.21e-05	9.62e-05	CcSEcCtD
Frovatriptan—Dizziness—Betamethasone—hematologic cancer	2.2e-05	9.59e-05	CcSEcCtD
Frovatriptan—Dizziness—Dexamethasone—hematologic cancer	2.2e-05	9.59e-05	CcSEcCtD
Frovatriptan—Hyperhidrosis—Epirubicin—hematologic cancer	2.19e-05	9.55e-05	CcSEcCtD
Frovatriptan—Insomnia—Methotrexate—hematologic cancer	2.19e-05	9.55e-05	CcSEcCtD
Frovatriptan—Chest pain—Doxorubicin—hematologic cancer	2.19e-05	9.54e-05	CcSEcCtD
Frovatriptan—Arthralgia—Doxorubicin—hematologic cancer	2.19e-05	9.54e-05	CcSEcCtD
Frovatriptan—Myalgia—Doxorubicin—hematologic cancer	2.19e-05	9.54e-05	CcSEcCtD
Frovatriptan—Anxiety—Doxorubicin—hematologic cancer	2.18e-05	9.51e-05	CcSEcCtD
Frovatriptan—Nausea—Triamcinolone—hematologic cancer	2.18e-05	9.5e-05	CcSEcCtD
Frovatriptan—Paraesthesia—Methotrexate—hematologic cancer	2.17e-05	9.48e-05	CcSEcCtD
Frovatriptan—Discomfort—Doxorubicin—hematologic cancer	2.16e-05	9.42e-05	CcSEcCtD
Frovatriptan—Anorexia—Epirubicin—hematologic cancer	2.16e-05	9.42e-05	CcSEcCtD
Frovatriptan—Dyspnoea—Methotrexate—hematologic cancer	2.16e-05	9.41e-05	CcSEcCtD
Frovatriptan—Somnolence—Methotrexate—hematologic cancer	2.15e-05	9.39e-05	CcSEcCtD
Frovatriptan—Dry mouth—Doxorubicin—hematologic cancer	2.14e-05	9.33e-05	CcSEcCtD
Frovatriptan—Hypersensitivity—Prednisone—hematologic cancer	2.13e-05	9.31e-05	CcSEcCtD
Frovatriptan—Dyspepsia—Methotrexate—hematologic cancer	2.13e-05	9.3e-05	CcSEcCtD
Frovatriptan—Vomiting—Dexamethasone—hematologic cancer	2.12e-05	9.23e-05	CcSEcCtD
Frovatriptan—Vomiting—Betamethasone—hematologic cancer	2.12e-05	9.23e-05	CcSEcCtD
Frovatriptan—Confusional state—Doxorubicin—hematologic cancer	2.11e-05	9.22e-05	CcSEcCtD
Frovatriptan—Decreased appetite—Methotrexate—hematologic cancer	2.11e-05	9.18e-05	CcSEcCtD
Frovatriptan—Anaphylactic shock—Doxorubicin—hematologic cancer	2.1e-05	9.14e-05	CcSEcCtD
Frovatriptan—Fatigue—Methotrexate—hematologic cancer	2.09e-05	9.1e-05	CcSEcCtD
Frovatriptan—Headache—Betamethasone—hematologic cancer	2.08e-05	9.09e-05	CcSEcCtD
Frovatriptan—Headache—Dexamethasone—hematologic cancer	2.08e-05	9.09e-05	CcSEcCtD
Frovatriptan—Asthenia—Prednisone—hematologic cancer	2.08e-05	9.07e-05	CcSEcCtD
Frovatriptan—Pain—Methotrexate—hematologic cancer	2.07e-05	9.03e-05	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.06e-05	9e-05	CcSEcCtD
Frovatriptan—Shock—Doxorubicin—hematologic cancer	2.06e-05	9e-05	CcSEcCtD
Frovatriptan—Pruritus—Prednisone—hematologic cancer	2.05e-05	8.94e-05	CcSEcCtD
Frovatriptan—Insomnia—Epirubicin—hematologic cancer	2.05e-05	8.94e-05	CcSEcCtD
Frovatriptan—Tachycardia—Doxorubicin—hematologic cancer	2.05e-05	8.92e-05	CcSEcCtD
Frovatriptan—Paraesthesia—Epirubicin—hematologic cancer	2.03e-05	8.87e-05	CcSEcCtD
Frovatriptan—Hyperhidrosis—Doxorubicin—hematologic cancer	2.03e-05	8.84e-05	CcSEcCtD
Frovatriptan—Dyspnoea—Epirubicin—hematologic cancer	2.02e-05	8.81e-05	CcSEcCtD
Frovatriptan—Somnolence—Epirubicin—hematologic cancer	2.01e-05	8.79e-05	CcSEcCtD
Frovatriptan—Anorexia—Doxorubicin—hematologic cancer	2e-05	8.72e-05	CcSEcCtD
Frovatriptan—Feeling abnormal—Methotrexate—hematologic cancer	2e-05	8.7e-05	CcSEcCtD
Frovatriptan—Dyspepsia—Epirubicin—hematologic cancer	1.99e-05	8.7e-05	CcSEcCtD
Frovatriptan—Diarrhoea—Prednisone—hematologic cancer	1.98e-05	8.65e-05	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Methotrexate—hematologic cancer	1.98e-05	8.64e-05	CcSEcCtD
Frovatriptan—Nausea—Dexamethasone—hematologic cancer	1.98e-05	8.62e-05	CcSEcCtD
Frovatriptan—Nausea—Betamethasone—hematologic cancer	1.98e-05	8.62e-05	CcSEcCtD
Frovatriptan—Decreased appetite—Epirubicin—hematologic cancer	1.97e-05	8.59e-05	CcSEcCtD
Frovatriptan—Fatigue—Epirubicin—hematologic cancer	1.95e-05	8.52e-05	CcSEcCtD
Frovatriptan—Pain—Epirubicin—hematologic cancer	1.94e-05	8.45e-05	CcSEcCtD
Frovatriptan—Constipation—Epirubicin—hematologic cancer	1.94e-05	8.45e-05	CcSEcCtD
Frovatriptan—Dizziness—Prednisone—hematologic cancer	1.92e-05	8.36e-05	CcSEcCtD
Frovatriptan—Abdominal pain—Methotrexate—hematologic cancer	1.91e-05	8.35e-05	CcSEcCtD
Frovatriptan—Body temperature increased—Methotrexate—hematologic cancer	1.91e-05	8.35e-05	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.91e-05	8.33e-05	CcSEcCtD
Frovatriptan—Insomnia—Doxorubicin—hematologic cancer	1.9e-05	8.27e-05	CcSEcCtD
Frovatriptan—Paraesthesia—Doxorubicin—hematologic cancer	1.88e-05	8.21e-05	CcSEcCtD
Frovatriptan—Dyspnoea—Doxorubicin—hematologic cancer	1.87e-05	8.15e-05	CcSEcCtD
Frovatriptan—Feeling abnormal—Epirubicin—hematologic cancer	1.87e-05	8.14e-05	CcSEcCtD
Frovatriptan—Somnolence—Doxorubicin—hematologic cancer	1.86e-05	8.13e-05	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Epirubicin—hematologic cancer	1.85e-05	8.08e-05	CcSEcCtD
Frovatriptan—Dyspepsia—Doxorubicin—hematologic cancer	1.85e-05	8.05e-05	CcSEcCtD
Frovatriptan—Vomiting—Prednisone—hematologic cancer	1.84e-05	8.03e-05	CcSEcCtD
Frovatriptan—Decreased appetite—Doxorubicin—hematologic cancer	1.82e-05	7.95e-05	CcSEcCtD
Frovatriptan—Headache—Prednisone—hematologic cancer	1.82e-05	7.92e-05	CcSEcCtD
Frovatriptan—Fatigue—Doxorubicin—hematologic cancer	1.81e-05	7.88e-05	CcSEcCtD
Frovatriptan—Pain—Doxorubicin—hematologic cancer	1.79e-05	7.82e-05	CcSEcCtD
Frovatriptan—Constipation—Doxorubicin—hematologic cancer	1.79e-05	7.82e-05	CcSEcCtD
Frovatriptan—Abdominal pain—Epirubicin—hematologic cancer	1.79e-05	7.81e-05	CcSEcCtD
Frovatriptan—Body temperature increased—Epirubicin—hematologic cancer	1.79e-05	7.81e-05	CcSEcCtD
Frovatriptan—Hypersensitivity—Methotrexate—hematologic cancer	1.78e-05	7.78e-05	CcSEcCtD
Frovatriptan—Asthenia—Methotrexate—hematologic cancer	1.74e-05	7.58e-05	CcSEcCtD
Frovatriptan—Feeling abnormal—Doxorubicin—hematologic cancer	1.73e-05	7.54e-05	CcSEcCtD
Frovatriptan—Nausea—Prednisone—hematologic cancer	1.72e-05	7.51e-05	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.71e-05	7.48e-05	CcSEcCtD
Frovatriptan—Pruritus—Methotrexate—hematologic cancer	1.71e-05	7.47e-05	CcSEcCtD
Frovatriptan—Hypersensitivity—Epirubicin—hematologic cancer	1.67e-05	7.28e-05	CcSEcCtD
Frovatriptan—Abdominal pain—Doxorubicin—hematologic cancer	1.66e-05	7.23e-05	CcSEcCtD
Frovatriptan—Body temperature increased—Doxorubicin—hematologic cancer	1.66e-05	7.23e-05	CcSEcCtD
Frovatriptan—Diarrhoea—Methotrexate—hematologic cancer	1.66e-05	7.23e-05	CcSEcCtD
Frovatriptan—Asthenia—Epirubicin—hematologic cancer	1.63e-05	7.09e-05	CcSEcCtD
Frovatriptan—Pruritus—Epirubicin—hematologic cancer	1.6e-05	6.99e-05	CcSEcCtD
Frovatriptan—Dizziness—Methotrexate—hematologic cancer	1.6e-05	6.98e-05	CcSEcCtD
Frovatriptan—Diarrhoea—Epirubicin—hematologic cancer	1.55e-05	6.76e-05	CcSEcCtD
Frovatriptan—Hypersensitivity—Doxorubicin—hematologic cancer	1.54e-05	6.74e-05	CcSEcCtD
Frovatriptan—Vomiting—Methotrexate—hematologic cancer	1.54e-05	6.71e-05	CcSEcCtD
Frovatriptan—Headache—Methotrexate—hematologic cancer	1.52e-05	6.62e-05	CcSEcCtD
Frovatriptan—Asthenia—Doxorubicin—hematologic cancer	1.5e-05	6.56e-05	CcSEcCtD
Frovatriptan—Dizziness—Epirubicin—hematologic cancer	1.5e-05	6.53e-05	CcSEcCtD
Frovatriptan—Pruritus—Doxorubicin—hematologic cancer	1.48e-05	6.47e-05	CcSEcCtD
Frovatriptan—Vomiting—Epirubicin—hematologic cancer	1.44e-05	6.28e-05	CcSEcCtD
Frovatriptan—Nausea—Methotrexate—hematologic cancer	1.44e-05	6.27e-05	CcSEcCtD
Frovatriptan—Diarrhoea—Doxorubicin—hematologic cancer	1.43e-05	6.26e-05	CcSEcCtD
Frovatriptan—Headache—Epirubicin—hematologic cancer	1.42e-05	6.19e-05	CcSEcCtD
Frovatriptan—Dizziness—Doxorubicin—hematologic cancer	1.39e-05	6.05e-05	CcSEcCtD
Frovatriptan—Nausea—Epirubicin—hematologic cancer	1.35e-05	5.87e-05	CcSEcCtD
Frovatriptan—Vomiting—Doxorubicin—hematologic cancer	1.33e-05	5.81e-05	CcSEcCtD
Frovatriptan—Headache—Doxorubicin—hematologic cancer	1.31e-05	5.73e-05	CcSEcCtD
Frovatriptan—Nausea—Doxorubicin—hematologic cancer	1.25e-05	5.43e-05	CcSEcCtD
Frovatriptan—CYP1A2—Metabolism—ARNTL—hematologic cancer	6.13e-06	0.000283	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—IL2—hematologic cancer	6.12e-06	0.000283	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—TERT—hematologic cancer	6.1e-06	0.000282	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PDGFB—hematologic cancer	6.08e-06	0.000281	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—PIK3R1—hematologic cancer	6.06e-06	0.00028	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CA9—hematologic cancer	5.96e-06	0.000275	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ACP5—hematologic cancer	5.96e-06	0.000275	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PDGFB—hematologic cancer	5.95e-06	0.000275	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—TSC2—hematologic cancer	5.94e-06	0.000274	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—JAK2—hematologic cancer	5.89e-06	0.000272	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—NCOR2—hematologic cancer	5.88e-06	0.000271	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—MAP2K1—hematologic cancer	5.87e-06	0.000271	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—GRB2—hematologic cancer	5.84e-06	0.000269	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—PIK3CD—hematologic cancer	5.83e-06	0.000269	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PDGFA—hematologic cancer	5.82e-06	0.000269	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—TSC2—hematologic cancer	5.82e-06	0.000269	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—KITLG—hematologic cancer	5.74e-06	0.000265	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—FGFR3—hematologic cancer	5.72e-06	0.000264	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—MAPK14—hematologic cancer	5.66e-06	0.000261	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—STAT5A—hematologic cancer	5.61e-06	0.000259	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—IDH1—hematologic cancer	5.6e-06	0.000259	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—FGFR3—hematologic cancer	5.6e-06	0.000258	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—PIK3CB—hematologic cancer	5.59e-06	0.000258	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CDKN2B—hematologic cancer	5.56e-06	0.000257	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—ESR1—hematologic cancer	5.55e-06	0.000256	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—MAPK14—hematologic cancer	5.54e-06	0.000256	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ABCC3—hematologic cancer	5.54e-06	0.000256	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—GSTO1—hematologic cancer	5.54e-06	0.000256	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—TXN—hematologic cancer	5.54e-06	0.000256	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—PIK3R1—hematologic cancer	5.5e-06	0.000254	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—FN1—hematologic cancer	5.49e-06	0.000253	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—ESR1—hematologic cancer	5.44e-06	0.000251	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—SPHK1—hematologic cancer	5.42e-06	0.00025	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—BAD—hematologic cancer	5.42e-06	0.00025	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—NFKBIA—hematologic cancer	5.42e-06	0.00025	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CD86—hematologic cancer	5.38e-06	0.000248	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—FN1—hematologic cancer	5.37e-06	0.000248	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—NOTCH1—hematologic cancer	5.37e-06	0.000248	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—JAK2—hematologic cancer	5.35e-06	0.000247	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—NFKBIA—hematologic cancer	5.31e-06	0.000245	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—BAD—hematologic cancer	5.31e-06	0.000245	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—HES1—hematologic cancer	5.3e-06	0.000245	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—NCOR1—hematologic cancer	5.27e-06	0.000243	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CD80—hematologic cancer	5.26e-06	0.000243	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—NOTCH1—hematologic cancer	5.26e-06	0.000243	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PIK3CG—hematologic cancer	5.25e-06	0.000242	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—KIT—hematologic cancer	5.25e-06	0.000242	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—NRAS—hematologic cancer	5.25e-06	0.000242	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—FGF1—hematologic cancer	5.21e-06	0.000241	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CSF2—hematologic cancer	5.21e-06	0.000241	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—UGT1A1—hematologic cancer	5.21e-06	0.00024	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PTPN11—hematologic cancer	5.16e-06	0.000238	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CD80—hematologic cancer	5.15e-06	0.000238	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PIK3CG—hematologic cancer	5.14e-06	0.000237	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—KIT—hematologic cancer	5.14e-06	0.000237	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—NRAS—hematologic cancer	5.14e-06	0.000237	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—FOXO1—hematologic cancer	5.14e-06	0.000237	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—IL2—hematologic cancer	5.14e-06	0.000237	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PDGFRB—hematologic cancer	5.13e-06	0.000237	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—PIK3CB—hematologic cancer	5.08e-06	0.000234	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—SLC22A1—hematologic cancer	5.07e-06	0.000234	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CRABP1—hematologic cancer	5.07e-06	0.000234	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PTPN11—hematologic cancer	5.05e-06	0.000233	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PDGFRA—hematologic cancer	5.05e-06	0.000233	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PRKCG—hematologic cancer	5.03e-06	0.000232	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—JAK1—hematologic cancer	5.03e-06	0.000232	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—MAPK3—hematologic cancer	5.03e-06	0.000232	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CREB1—hematologic cancer	5e-06	0.000231	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ALOX5—hematologic cancer	4.94e-06	0.000228	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—BRAF—hematologic cancer	4.93e-06	0.000228	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—MAPK3—hematologic cancer	4.92e-06	0.000227	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CREB1—hematologic cancer	4.89e-06	0.000226	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CCL2—hematologic cancer	4.89e-06	0.000226	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—IL6R—hematologic cancer	4.87e-06	0.000225	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CREBBP—hematologic cancer	4.87e-06	0.000225	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—BRAF—hematologic cancer	4.83e-06	0.000223	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CCL2—hematologic cancer	4.79e-06	0.000221	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—NUP98—hematologic cancer	4.78e-06	0.000221	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—IL6R—hematologic cancer	4.77e-06	0.00022	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CREBBP—hematologic cancer	4.77e-06	0.00022	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—IL2RA—hematologic cancer	4.7e-06	0.000217	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—IL2—hematologic cancer	4.66e-06	0.000215	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—TERT—hematologic cancer	4.65e-06	0.000214	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—MAP2K1—hematologic cancer	4.65e-06	0.000214	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ADCY7—hematologic cancer	4.64e-06	0.000214	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—NCOA3—hematologic cancer	4.64e-06	0.000214	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PIK3CD—hematologic cancer	4.62e-06	0.000213	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—NUP214—hematologic cancer	4.61e-06	0.000213	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—PIK3CA—hematologic cancer	4.57e-06	0.000211	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	4.56e-06	0.000211	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—MAP2K1—hematologic cancer	4.55e-06	0.00021	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PDGFB—hematologic cancer	4.54e-06	0.000209	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PIK3CD—hematologic cancer	4.52e-06	0.000209	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—KRAS—hematologic cancer	4.52e-06	0.000208	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ABCG2—hematologic cancer	4.52e-06	0.000208	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—MTR—hematologic cancer	4.52e-06	0.000208	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—PIK3CA—hematologic cancer	4.48e-06	0.000207	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—TSC2—hematologic cancer	4.43e-06	0.000205	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ENO2—hematologic cancer	4.43e-06	0.000204	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—KRAS—hematologic cancer	4.42e-06	0.000204	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—FGF2—hematologic cancer	4.42e-06	0.000204	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PIK3R1—hematologic cancer	4.36e-06	0.000201	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—FGF2—hematologic cancer	4.33e-06	0.0002	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—GSTT1—hematologic cancer	4.3e-06	0.000198	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PIK3R1—hematologic cancer	4.27e-06	0.000197	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—FGFR3—hematologic cancer	4.27e-06	0.000197	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—JAK2—hematologic cancer	4.24e-06	0.000195	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	4.23e-06	0.000195	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—MAPK14—hematologic cancer	4.22e-06	0.000195	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—SDC1—hematologic cancer	4.2e-06	0.000194	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—PIK3CA—hematologic cancer	4.15e-06	0.000192	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—JAK2—hematologic cancer	4.15e-06	0.000191	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—ESR1—hematologic cancer	4.14e-06	0.000191	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—MDM2—hematologic cancer	4.13e-06	0.000191	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—FN1—hematologic cancer	4.09e-06	0.000189	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—PIK3CA—hematologic cancer	4.06e-06	0.000188	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—MDM2—hematologic cancer	4.05e-06	0.000187	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—NFKBIA—hematologic cancer	4.04e-06	0.000187	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—BAD—hematologic cancer	4.04e-06	0.000187	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PIK3CB—hematologic cancer	4.02e-06	0.000186	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—MTOR—hematologic cancer	4.02e-06	0.000186	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	4.01e-06	0.000185	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—NOTCH1—hematologic cancer	4e-06	0.000185	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	3.96e-06	0.000183	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PIK3CB—hematologic cancer	3.94e-06	0.000182	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—MTOR—hematologic cancer	3.94e-06	0.000182	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CD80—hematologic cancer	3.92e-06	0.000181	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PIK3CG—hematologic cancer	3.92e-06	0.000181	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—KIT—hematologic cancer	3.92e-06	0.000181	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—NRAS—hematologic cancer	3.92e-06	0.000181	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PTPN11—hematologic cancer	3.85e-06	0.000178	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—HRAS—hematologic cancer	3.84e-06	0.000177	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	3.79e-06	0.000175	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CDKN1B—hematologic cancer	3.78e-06	0.000174	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—HRAS—hematologic cancer	3.76e-06	0.000174	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—MAPK3—hematologic cancer	3.75e-06	0.000173	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—AKT1—hematologic cancer	3.73e-06	0.000172	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CREB1—hematologic cancer	3.73e-06	0.000172	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CASP3—hematologic cancer	3.7e-06	0.000171	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CDKN1B—hematologic cancer	3.7e-06	0.000171	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—IL2—hematologic cancer	3.69e-06	0.00017	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—BRAF—hematologic cancer	3.68e-06	0.00017	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—IL6—hematologic cancer	3.68e-06	0.00017	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—AKT1—hematologic cancer	3.66e-06	0.000169	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CCL2—hematologic cancer	3.65e-06	0.000168	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—IL6R—hematologic cancer	3.64e-06	0.000168	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CREBBP—hematologic cancer	3.63e-06	0.000168	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CASP3—hematologic cancer	3.62e-06	0.000167	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—IL2—hematologic cancer	3.62e-06	0.000167	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CCND1—hematologic cancer	3.6e-06	0.000166	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—IL6—hematologic cancer	3.6e-06	0.000166	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—JUN—hematologic cancer	3.59e-06	0.000166	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—NQO1—hematologic cancer	3.57e-06	0.000165	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CD44—hematologic cancer	3.57e-06	0.000165	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CCND1—hematologic cancer	3.53e-06	0.000163	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—JUN—hematologic cancer	3.52e-06	0.000162	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	3.5e-06	0.000161	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CDKN1A—hematologic cancer	3.48e-06	0.000161	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PTEN—hematologic cancer	3.48e-06	0.00016	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—MAP2K1—hematologic cancer	3.47e-06	0.00016	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PIK3CD—hematologic cancer	3.44e-06	0.000159	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CDKN1A—hematologic cancer	3.41e-06	0.000157	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—PIK3CA—hematologic cancer	3.41e-06	0.000157	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PTEN—hematologic cancer	3.4e-06	0.000157	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—MAPK8—hematologic cancer	3.4e-06	0.000157	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—AKT1—hematologic cancer	3.39e-06	0.000156	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CYCS—hematologic cancer	3.38e-06	0.000156	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—KRAS—hematologic cancer	3.37e-06	0.000156	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	3.36e-06	0.000155	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—MAPK8—hematologic cancer	3.33e-06	0.000154	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—AKT1—hematologic cancer	3.32e-06	0.000153	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—EP300—hematologic cancer	3.32e-06	0.000153	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—FGF2—hematologic cancer	3.3e-06	0.000152	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PIK3R1—hematologic cancer	3.25e-06	0.00015	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—EP300—hematologic cancer	3.25e-06	0.00015	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—SRC—hematologic cancer	3.22e-06	0.000149	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—JAK2—hematologic cancer	3.16e-06	0.000146	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—SRC—hematologic cancer	3.16e-06	0.000146	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—VEGFA—hematologic cancer	3.14e-06	0.000145	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—STAT3—hematologic cancer	3.11e-06	0.000143	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—NRAS—hematologic cancer	3.1e-06	0.000143	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—PIK3CA—hematologic cancer	3.1e-06	0.000143	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—MDM2—hematologic cancer	3.08e-06	0.000142	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—VEGFA—hematologic cancer	3.07e-06	0.000142	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—STAT3—hematologic cancer	3.04e-06	0.00014	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—NRAS—hematologic cancer	3.04e-06	0.00014	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.02e-06	0.000139	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—MTOR—hematologic cancer	3e-06	0.000138	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PIK3CB—hematologic cancer	3e-06	0.000138	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—GSTP1—hematologic cancer	2.98e-06	0.000137	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—MAPK3—hematologic cancer	2.97e-06	0.000137	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—MAPK3—hematologic cancer	2.91e-06	0.000134	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—MYC—hematologic cancer	2.89e-06	0.000133	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—TGFB1—hematologic cancer	2.88e-06	0.000133	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.88e-06	0.000133	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—HRAS—hematologic cancer	2.86e-06	0.000132	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—MYC—hematologic cancer	2.83e-06	0.000131	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—TGFB1—hematologic cancer	2.82e-06	0.00013	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ABCB1—hematologic cancer	2.82e-06	0.00013	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CDKN1B—hematologic cancer	2.82e-06	0.00013	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—AKT1—hematologic cancer	2.79e-06	0.000129	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CASP3—hematologic cancer	2.76e-06	0.000127	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—IL2—hematologic cancer	2.76e-06	0.000127	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—IL6—hematologic cancer	2.74e-06	0.000127	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—GSTM1—hematologic cancer	2.74e-06	0.000126	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—NCOR1—hematologic cancer	2.74e-06	0.000126	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CCND1—hematologic cancer	2.69e-06	0.000124	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—JUN—hematologic cancer	2.68e-06	0.000124	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—KRAS—hematologic cancer	2.67e-06	0.000123	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—KRAS—hematologic cancer	2.61e-06	0.000121	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CDKN1A—hematologic cancer	2.6e-06	0.00012	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PTEN—hematologic cancer	2.59e-06	0.00012	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—MAPK8—hematologic cancer	2.54e-06	0.000117	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—AKT1—hematologic cancer	2.53e-06	0.000117	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—EP300—hematologic cancer	2.47e-06	0.000114	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PIK3CA—hematologic cancer	2.45e-06	0.000113	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—MTHFR—hematologic cancer	2.42e-06	0.000112	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—SRC—hematologic cancer	2.4e-06	0.000111	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PIK3CA—hematologic cancer	2.4e-06	0.000111	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—TP53—hematologic cancer	2.37e-06	0.000109	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—VEGFA—hematologic cancer	2.34e-06	0.000108	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—TP53—hematologic cancer	2.32e-06	0.000107	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—STAT3—hematologic cancer	2.32e-06	0.000107	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—NRAS—hematologic cancer	2.31e-06	0.000107	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—HRAS—hematologic cancer	2.27e-06	0.000105	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—HRAS—hematologic cancer	2.22e-06	0.000102	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—MAPK3—hematologic cancer	2.22e-06	0.000102	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—IL6—hematologic cancer	2.17e-06	0.0001	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—MYC—hematologic cancer	2.15e-06	9.94e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	2.15e-06	9.92e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.13e-06	9.83e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—IL6—hematologic cancer	2.13e-06	9.81e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PIK3CG—hematologic cancer	2.03e-06	9.37e-05	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—AKT1—hematologic cancer	2e-06	9.24e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—KRAS—hematologic cancer	1.99e-06	9.19e-05	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—AKT1—hematologic cancer	1.96e-06	9.05e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CREBBP—hematologic cancer	1.88e-06	8.69e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	1.83e-06	8.44e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PIK3CD—hematologic cancer	1.79e-06	8.24e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—TP53—hematologic cancer	1.77e-06	8.16e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ALB—hematologic cancer	1.76e-06	8.14e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—HRAS—hematologic cancer	1.69e-06	7.81e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PIK3R1—hematologic cancer	1.69e-06	7.78e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—IL6—hematologic cancer	1.62e-06	7.47e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PIK3CB—hematologic cancer	1.56e-06	7.18e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—AKT1—hematologic cancer	1.49e-06	6.89e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PTEN—hematologic cancer	1.35e-06	6.21e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—EP300—hematologic cancer	1.28e-06	5.92e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PIK3CA—hematologic cancer	9.49e-07	4.38e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—AKT1—hematologic cancer	7.75e-07	3.58e-05	CbGpPWpGaD
